Leverage the speed and scalability of FastPharming to rapidly produce COVID-19 biologics.Combat COVID-19 with FastPharming
Production of a range of recombinant products including monoclonal antibodies, antigens for subunit vaccine design, lysosomal enzymes, and many moreExplore FastPharming
Full range of development and manufacturing services required to move projects from pre-clinical, market launch, to ongoing commercial requirements phasesLearn More About iBio's Services
Plant-based expression shortens development timelines and provides for seamless scale-up. Glycan engineering in plants affords greater control and can deliver increased product potency and quality.Explore FastPharming
FastPharming overcomes issues presented by mammalian expression systems:
FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.
The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.
In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.
An experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.
When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.
The FastPharming platform produces a variety of recombinant products including:
iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.